

EVOLVING MYELOFIBROSIS TREATMENT OPTIONS: WHAT YOU SHOULD KNOW



Program Resource Guide

Glossary Terms

Anemia (iron deficiency anemia): A condition that develops when the body lacks sufficient red blood cells. Symptoms of anemia may include fatigue, weakness, and shortness of breath, among others.

Genetic Testing (molecular profiling or biomarker testing): Laboratory testing that identifies certain gene mutations, proteins, chromosomal abnormalities and/or other molecular changes that are unique to an individual's disease. In cancer, it may be used to evaluate treatment or to make a prognosis.

JAK2 (JAK2V617F) Mutation: An acquired mutation in the majority of patients with myeloproliferative neoplasms. The mutation is found in approximately 50% of myelofibrosis (MF) and essential thrombocythemia (ET) patients and 95% of polycythemia vera (PV) patients.

Splenomegaly: Enlarged spleen.

Stem Cell Transplant (bone marrow transplant): Procedure in which healthy blood stem cells are used to replace damaged or diseased bone marrow. This procedure can be used to treat certain types of blood cancers.

Tissue Bank: An organization that collects, stores, and distributes human biological specimens for research purposes.

Therapies Being Studied to Treat Myelofibrosis

- Pelabresib (BET inhibitor)
- Navitoclax (BCLXL-BCL2 inhibitor)
- Selinexor (Xpovio)
- Navtemadlin (MDM2 inhibitor)
- PIM1 kinase inhibitor (TP-3654)
- Lysyl oxidase (LOX) inhibitor
- LSD1 inhibitor

JAK Inhibitors

JAK Inhibitors: A class of therapy that interferes with the activation of the JAK-STAT pathway.

Approved JAK Inhibitors for Myelofibrosis:

- Ruxolitinib (Jakafi)
- Pacritinib (Vonjo)
- Fedratinib (Inrebic)
- Momelotinib (Ojjaara)

Questions to Ask About Clinical Trials

- What medicine will I receive?
- Is there a placebo?
- What group will I be assigned to?
- What phase is the study?
- What is the time commitment?
- Are there any financial reimbursements?

Educational Resources

LLS | [Clinical Trials](#)

PEN | [Office Visit Planners](#)

Thank You
Cancer Support Community
CancerGRACE
CURE
The Leukemia & Lymphoma Society (LLS)

Evolve Myelofibrosis is brought to you by the Patient Empowerment Network. Funding is provided by a sponsorship from Merck, MorphoSys, and through generous donations from people like you.



www.powerfulpatients.org